Newsletter
Clinical Trial Update
News filed under Clinical Trial Update, newest first.
Showing 1–5 of 10 stories
Latest story
Lumen Bioscience Reports Positive Phase 2 Results for Oral LMN-201 in C. difficile Infection
Investigational biologic LMN-201 achieved an 83.3% global cure rate and a six-fold reduction in infe...
Read story
Roche Reports Promising Phase III Fenebrutinib Results in Multiple Sclerosis
Investigational therapy reduced chronic active brain lesion markers and annualised relapse rates, wh...
Read story
Paradigm Therapeutics Enrolls First Patient in Phase 3 Trial of SD-101 for Epidermolysis Bullosa
Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatm...
Read story
Neurocrine Biosciences Publishes New Insights on Hyperphagia in Prader-Willi Syndrome
Published in the Orphanet Journal of Rare Diseases, the manuscript brings together insights from an...
Read story
Lakewood-Amedex Presents Nu-3 Antimicrobial Data at IDWeek 2026
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT), a clinical-stage biotechnology company developi...
Read storyPage 1 of 2
